Abstract

BackgroundEstimation of phosphate load in hemodialysis patients is always controversial in clinical practice. The aim of this study was to verify individual achievement rate of serum phosphate as the evaluation of phosphate load through investigating its impact on cardiovascular mortality in hemodialysis patients.MethodsThis was a single-center, retrospective cohort study. A total of 251 maintenance hemodialysis patients were enrolled. The individual achievement rate of serum phosphate was defined as the times of tests within the target range divided by total times of tests over a period of time. Cox regression model was used to examine the relationship between individual achievement rate of serum phosphate and cardiovascular mortality.ResultsThe mean age of the study population was 61 ± 13 years old. A total of 44 (17.5%) patients died from cardiovascular disease (CVD) during a median follow-up of 65 months. Multivariable Cox analysis showed that one-year serum phosphate achievement rate of 0% (HR = 4.117, P = 0.016) and 25% (HR = 3.343, P = 0.023) increased the risk of cardiovascular mortality while the achievement rate of 50% (HR = 2.129, P = 0.162) and 75% (HR = 1.080, P = 0.902) did not, compared to the rate of 100%. Urea reduction ratio (URR) was positively, while serum intact parathyroid hormone (iPTH), alkaline phosphatase (ALP), normalized protein catabolic rate (nPCR), and total phosphate-binding capacity of drug were negatively associated with achievement in target of serum phosphate.ConclusionsKeeping one-year achievement rate of serum phosphate higher than 50% provides significant clinical benefits in reducing cardiovascular mortality.

Highlights

  • Hyperphosphatemia is one of common complications in maintenance hemodialysis (MHD) patients which causes poor prognosis

  • Baseline characteristics A total of 251 hemodialysis patients from Huashan Hospital were enrolled in this study including 178 patients receiving hemodialysis before research and 73 patients new to hemodialysis

  • We found that serum intact parathyroid hormone (iPTH) level (HR = 0.922, P < 0.001, 95%CI: 0.903– 0.950), alkaline phosphatase (ALP) (HR = 0.957, P < 0.001, 95%CI: 0.967–0.983), normalized protein catabolic rate (nPCR) (HR = 0.114, P < 0.001, 95%CI: 0.036–0.366), Urea reduction ratio (URR) (HR = 2.259, P = 0.007, 95%CI: 2.393–3.924) and total phosphate-binding capacity of drug (HR = 0.997, P = 0.023, 95%CI: 0.995–0.999) were significantly correlated with target achievement of serum phosphate (Table 4)

Read more

Summary

Introduction

Hyperphosphatemia is one of common complications in maintenance hemodialysis (MHD) patients which causes poor prognosis. It is obvious that serum phosphate level is far from well-controlled worldwide. This may be due to the exchange between serum phosphate and phosphate pool. Researchers believe that phosphate pool may reflect phosphate retention since it explains the rebound of serum phosphate level after hemodialysis treatment [4]. We propose that phosphate load, which contains phosphate pool and serum phosphate, is a biomarker for phosphate retention in hemodialysis patients. Estimation of phosphate load in hemodialysis patients is always controversial in clinical practice. The aim of this study was to verify individual achievement rate of serum phosphate as the evaluation of phosphate load through investigating its impact on cardiovascular mortality in hemodialysis patients

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call